Tags

Type your tag names separated by a space and hit enter

Clinical validation of 3 commercial real-time reverse transcriptase polymerase chain reaction assays for the detection of Middle East respiratory syndrome coronavirus from upper respiratory tract specimens.
Diagn Microbiol Infect Dis. 2017 Apr; 87(4):320-324.DM

Abstract

Since discovery of Middle East respiratory syndrome coronavirus (MERS-CoV), a novel betacoronavirus first isolated and characterized in 2012, MERS-CoV real-time reverse transcriptase polymerase chain reaction (rRT-PCR) assays represent one of the most rapidly expanding commercial tests. However, in the absence of extensive evaluations of these assays on positive clinical material of different sources, evaluating their diagnostic effectiveness remains challenging. We describe the diagnostic performance evaluation of 3 common commercial MERS-CoV rRT-PCR assays on a large panel (n = 234) of upper respiratory tract specimens collected during an outbreak episode in Saudi Arabia. Assays were compared to the RealStar® MERS-CoV RT-PCR (Alton Diagnostics, Hamburg, Germany) assay as the gold standard. Results showed i) the TIB MolBiol® LightMix UpE and Orf1a assays (TIB MolBiol, Berlin, Germany) to be the most sensitive, followed by ii) the Anyplex™ Seegene MERS-CoV assay (Seegene, Seoul, Korea), and finally iii) the PrimerDesign™ Genesig® HCoV_2012 assay (PrimerDesign, England, United Kingdom). We also evaluate a modified protocol for the PrimerDesign™ Genesig® HCoV_2012 assay.

Authors+Show Affiliations

Pathology/Microbiology Division, College of Medicine, King Saud University, Riyadh, Saudi Arabia. Electronic address: dmohamed@ksu.edu.sa.Pathology/Microbiology Division, College of Medicine, King Saud University, Riyadh, Saudi Arabia.Transfusion Microbiology Department, College of Medicine, King Saud University, Riyadh, Saudi Arabia.Central Blood Bank, Riyadh, Saudi Arabia.Department of Pediatrics, College of Medicine, King Saud University, Riyadh, Saudi Arabia.Pathology/Microbiology Division, College of Medicine, King Saud University, Riyadh, Saudi Arabia.

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

28104327

Citation

Mohamed, Deqa H., et al. "Clinical Validation of 3 Commercial Real-time Reverse Transcriptase Polymerase Chain Reaction Assays for the Detection of Middle East Respiratory Syndrome Coronavirus From Upper Respiratory Tract Specimens." Diagnostic Microbiology and Infectious Disease, vol. 87, no. 4, 2017, pp. 320-324.
Mohamed DH, AlHetheel AF, Mohamud HS, et al. Clinical validation of 3 commercial real-time reverse transcriptase polymerase chain reaction assays for the detection of Middle East respiratory syndrome coronavirus from upper respiratory tract specimens. Diagn Microbiol Infect Dis. 2017;87(4):320-324.
Mohamed, D. H., AlHetheel, A. F., Mohamud, H. S., Aldosari, K., Alzamil, F. A., & Somily, A. M. (2017). Clinical validation of 3 commercial real-time reverse transcriptase polymerase chain reaction assays for the detection of Middle East respiratory syndrome coronavirus from upper respiratory tract specimens. Diagnostic Microbiology and Infectious Disease, 87(4), 320-324. https://doi.org/10.1016/j.diagmicrobio.2017.01.003
Mohamed DH, et al. Clinical Validation of 3 Commercial Real-time Reverse Transcriptase Polymerase Chain Reaction Assays for the Detection of Middle East Respiratory Syndrome Coronavirus From Upper Respiratory Tract Specimens. Diagn Microbiol Infect Dis. 2017;87(4):320-324. PubMed PMID: 28104327.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical validation of 3 commercial real-time reverse transcriptase polymerase chain reaction assays for the detection of Middle East respiratory syndrome coronavirus from upper respiratory tract specimens. AU - Mohamed,Deqa H, AU - AlHetheel,AbdulKarim F, AU - Mohamud,Hanat S, AU - Aldosari,Kamel, AU - Alzamil,Fahad A, AU - Somily,Ali M, Y1 - 2017/01/10/ PY - 2016/09/13/received PY - 2017/01/02/revised PY - 2017/01/04/accepted PY - 2017/1/21/pubmed PY - 2017/3/11/medline PY - 2017/1/21/entrez KW - MERS-CoV KW - Orf1a KW - RT-PCR KW - Saudi Arabia KW - UpE SP - 320 EP - 324 JF - Diagnostic microbiology and infectious disease JO - Diagn Microbiol Infect Dis VL - 87 IS - 4 N2 - Since discovery of Middle East respiratory syndrome coronavirus (MERS-CoV), a novel betacoronavirus first isolated and characterized in 2012, MERS-CoV real-time reverse transcriptase polymerase chain reaction (rRT-PCR) assays represent one of the most rapidly expanding commercial tests. However, in the absence of extensive evaluations of these assays on positive clinical material of different sources, evaluating their diagnostic effectiveness remains challenging. We describe the diagnostic performance evaluation of 3 common commercial MERS-CoV rRT-PCR assays on a large panel (n = 234) of upper respiratory tract specimens collected during an outbreak episode in Saudi Arabia. Assays were compared to the RealStar® MERS-CoV RT-PCR (Alton Diagnostics, Hamburg, Germany) assay as the gold standard. Results showed i) the TIB MolBiol® LightMix UpE and Orf1a assays (TIB MolBiol, Berlin, Germany) to be the most sensitive, followed by ii) the Anyplex™ Seegene MERS-CoV assay (Seegene, Seoul, Korea), and finally iii) the PrimerDesign™ Genesig® HCoV_2012 assay (PrimerDesign, England, United Kingdom). We also evaluate a modified protocol for the PrimerDesign™ Genesig® HCoV_2012 assay. SN - 1879-0070 UR - https://www.unboundmedicine.com/medline/citation/28104327/Clinical_validation_of_3_commercial_real_time_reverse_transcriptase_polymerase_chain_reaction_assays_for_the_detection_of_Middle_East_respiratory_syndrome_coronavirus_from_upper_respiratory_tract_specimens_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0732-8893(17)30007-X DB - PRIME DP - Unbound Medicine ER -